T0	Participants 112 127	ovarian cancer.
T1	Participants 321 341	ovarian cancer (OC).
T2	Participants 350 378	Patients with stage IC-IV OC
T3	Participants 601 637	Patients with complete response (CR)
T4	Participants 874 883	toxicity.
T5	Participants 884 911	PD or death in 636 patients
T6	Participants 1087 1140	by 820 of 919 patients enrolled; 352 patients with CR
T7	Participants 1175 1206	whereas 155 patients without CR